Tech Company Financing Transactions
Anavo Therapeutics Funding Round
On 5/2/2023, Anavo Therapeutics landed $9.4 million in Seed investment from Bioqube Ventures, INKEF Capital and M Ventures.
Transaction Overview
Company Name
Announced On
5/2/2023
Transaction Type
Venture Equity
Amount
$9,392,000
Round
Seed
Proceeds Purpose
The company intends to use the funds to accelerate its proprietary portfolio of programs targeting disease-relevant phosphatases toward clinical development.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
J.H. Oortweg 19
Leiden, 2333
CH
Leiden, 2333
CH
Phone
Undisclosed
Website
Email Address
Overview
Anavo Therapeutics is the first company to systematically drug phosphatases, a rich target space previously considered undruggable for decades. We have attracted world-leading scientific expertise in phosphatase-driven disease biology and drug discovery to unlock the full potential of phosphatase-targeted allosteric modulators. In oncology, Anavo is developing multiple first-in-class therapeutic programs and will build on partnerships around its platform to establish a rich pipeline across several indications.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Birgit Zech
Chief Scientific Officer
Gerhard Müller
Browse more venture capital transactions:
Prev: 5/2/2023: Altris venture capital transaction
Next: 5/2/2023: BayWa r.e. venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on every notable VC transaction. All VC database entries reported here come from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs